ArticlePeerJ2023
Fluoroquinolone resistance determinants in carbapenem-resistant
Article in PeerJ, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 14 citations in OpenAlex.
- Antimicrobial Resistance, Biofilm Formation, and Phylogenetic Distribution ofAntibiotics (Basel, Switzerland) · 2026Article
- Genomic characterization of multidrug-resistant Escherichia coli strains identified from patients with urinary tract infection in Egypt.Scientific reports · 2026Article
- Fluoroquinolone-Resistant Avian PathogenicPathogens (Basel, Switzerland) · 2026Article
- Antibiogram of isolated bacteria and overview of resistome and virulome of multi-drug resistant Escherichia coli from ready-to-eat foods vended in Lagos, Nigeria.BMC microbiology · 2026Article
- Genomic insights into selected multidrug-resistant and ESBL-producing uropathogenicFrontiers in microbiology · 2026Article
- Current Insights into Antibiotic Resistance in UropathogenicAntibiotics (Basel, Switzerland) · 2025Review
- Genetic Determinants of Carbapenem and Fluoroquinolone Resistance inInfection & chemotherapy · 2025Article
- Genomic Characterization of Carbapenemase-Producing Enterobacteriaceae from Clinical and Epidemiological Human Samples.Antibiotics (Basel, Switzerland) · 2025Article
- Mechanisms of fluoroquinolone resistance among Escherichia coli isolates from urinary tract infections in Thailand.PloS one · 2025Article
- Molecular epidemiology of carbapenem-resistantPeerJ · 2025Article
- The Impact of Urinary Catheterization on the Antibiotic Susceptibility of ESBL-Producing Enterobacterales: A Challenging Duo.Antibiotics (Basel, Switzerland) · 2024Article
- SWOT and Root Cause Analyses of Antimicrobial Resistance to Oral Antimicrobial Treatment of Cystitis.Antibiotics (Basel, Switzerland) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Objectives: To characterize FQ-resistant determinants among 103 carbapenem-resistant Methods: Antimicrobial susceptibility, biofilm formation, and short-read sequencing were applied to these isolates. Complete genome sequencing of five CREcs was conducted using short- and long-read platforms. Results: ST410 (50.49%) was the predominant ST, followed by ST405 (12.62%) and ST361 (11.65%). Clermont phylogroup C (54.37%) was the most frequent. The genes Conclusions: This study showed FQ-resistant determinants in urinary CREc isolates that could be a warning sign to adopt efficient strategies or new control policies to prevent further spread and to help in monitoring this microorganism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.